← Back to Search

Telehealth Advance Care Planning for Myeloid Leukemia (TeleSICP Trial)

N/A
Waitlist Available
Research Sponsored by University of Rochester
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up throughout the study, up to 2 years
Awards & highlights

TeleSICP Trial Summary

This trial will assess if a telehealth-delivered program helps older patients with blood cancers communicate better with healthcare providers, reduce anxiety/distress, & complete advance directives.

Who is the study for?
This trial is for individuals aged 60 or older with certain blood disorders, including acute myeloid leukemia and myelodysplastic syndrome. Participants must be receiving outpatient care, able to give informed consent, and speak English.Check my eligibility
What is being tested?
The study is testing a telehealth program designed to improve healthcare communication and reduce patient anxiety. It also aims to increase the completion of advance directives like MOLST (medical orders for life-sustaining treatment) forms.See study design
What are the potential side effects?
Since this trial involves an educational intervention rather than medication, traditional physical side effects are not expected. However, discussing serious illness may cause emotional discomfort.

TeleSICP Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~throughout the study, up to 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and throughout the study, up to 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Healthcare Communication: Health Care Climate Questionnaire
Secondary outcome measures
Anxiety Symptoms: Generalized Anxiety Disorder-7 (GAD-7)
Completion of advance directives
Distress: Distress Thermometer

TeleSICP Trial Design

2Treatment groups
Experimental Treatment
Group I: Telehealth Serious Illness Care ProgramExperimental Treatment1 Intervention
The adapted telehealth Serious Illness Care Program is a multilevel intervention engaging the patient, caregiver, clinician, and system. It consists of tools, training, and system change. Tools include: 1) The Serious Illness Conversation Guide for clinicians; and 2) Education materials for patients on the importance of Serious Illness Conversations (Patient Preparation Pamphlet) and of the involvement of caregivers (Family Communication Guide).
Group II: ControlExperimental Treatment1 Intervention
Education materials developed by the NCI on "Communication in Cancer Care (PDQ®) - Patient Version"

Find a Location

Who is running the clinical trial?

University of RochesterLead Sponsor
836 Previous Clinical Trials
517,961 Total Patients Enrolled

Media Library

Telehealth Serious Illness Care Program Clinical Trial Eligibility Overview. Trial Name: NCT05875805 — N/A
Myelofibrosis Research Study Groups: Control, Telehealth Serious Illness Care Program
Myelofibrosis Clinical Trial 2023: Telehealth Serious Illness Care Program Highlights & Side Effects. Trial Name: NCT05875805 — N/A
Telehealth Serious Illness Care Program 2023 Treatment Timeline for Medical Study. Trial Name: NCT05875805 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are new participants being accepted to join this clinical experiment?

"As stated on clinicaltrials.gov, this specific study is not currently accepting patients. Initially posted to the website October 1st 2023 and last updated May 16th 2023, this trial is not presently recruiting participants; however, 3312 other trials are actively looking for volunteers right now."

Answered by AI
~138 spots leftby Sep 2025